Intellipharmaceutics International Inc. has announced that, FDA; USA, has reviewed the Company’s request for Fast Track designation for its abuse deterrent Rexista(TM) Oxycodone XR (Oxycodone HCl) extended-release tablets development program.
Besides FDA has concluded that it meets the criteria for Fast Track designation.
View the full release here.